1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Viracept® (Nelfinavir Mesylate) Tablets, 250 and 625 mg
Trade Name: Viracept
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as HIV protease inhibitor

Details of the Supplier of the Safety Data Sheet

ViiV Healthcare
Five Moore Drive
Research Triangle Park
North Carolina 27709-3398
+1 877 ViiVUSA (+1 877 844 8872)

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified
Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colloidal silicon dioxide</td>
<td>7631-86-9</td>
<td>231-545-4</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>
3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nelfinavir Mesylate</td>
<td>159989-65-8</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>40-65</td>
</tr>
<tr>
<td>Hydroxypropyl methylcellulose</td>
<td>9004-65-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Crospovidone</td>
<td>9003-39-8</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>FD&amp;C Blue No. 2</td>
<td>860-22-0</td>
<td>212-728-8</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Calcium stearate</td>
<td>1592-23-0</td>
<td>216-472-8</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Triacetin</td>
<td>102-76-1</td>
<td>203-051-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:  
* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures  
Eye Contact:  
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:  
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion:  
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:  
Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed  
Symptoms and Effects of Exposure:  
For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure:  
None known

Indication of the Immediate Medical Attention and Special Treatment Needed  
Notes to Physician:  
None

5. FIRE FIGHTING MEASURES

Extinguishing Media:  
Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture  
Hazardous Combustion Products:  
Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards:  
Not applicable

Advice for Fire-Fighters  
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
- Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
- Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
- Storage Conditions: Store as directed by product packaging.
- Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
- Refer to available public information for specific member state Occupational Exposure Limits.

Colloidal silicon dioxide
- Australia TWA: 2 mg/m³
- Austria OEL - MAKs: 4 mg/m³
- Czech Republic OEL - TWA: 0.1 mg/m³
- Estonia OEL - TWA: 2 mg/m³
- Finland OEL - TWA: 5 mg/m³
- Germany - TRGS 900 - TWAs: 4 mg/m³
- Germany (DFG) - MAK: 4 mg/m³
- Ireland OEL - TWAs: 6 mg/m³
- Latvia OEL - TWA: 1 mg/m³
- OSHA - Final PELs - Table Z-3 Mineral D: Listed
- Slovakia OEL - TWA: 4.0 mg/m³
- Slovenia OEL - TWA: 0.3 mg/m³
- Switzerland OEL -TWAs: 4 mg/m³

Magnesium stearate
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Tablet

Color: Light blue, White to off-white

Odor: No data available.

Molecular Formula: Mixture

Molecular Weight: Mixture

Solvent Solubility: No data available

Water Solubility: No data available

pH: No data available.

Melting/Freezing Point (°C): No data available

Boiling Point (°C): No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Crosopodide
No data available

Magnesium stearate

Sweden OEL - TWAs

Molecular Formula: Mixture

Molecular Weight: Mixture

Calcium stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³

Lithuania OEL - TWA 5 mg/m³

Sweden OEL - TWAs 5 mg/m³

Nelfinavir Mesylate

Pfizer OEL TWA-8 Hr: 3000µg/m³

Calcium stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³

Lithuania OEL - TWA 5 mg/m³

Sweden OEL - TWAs 5 mg/m³
9. PHYSICAL AND CHEMICAL PROPERTIES

Decomposition Temperature (°C): No data available
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: Dust may cause irritation. Active ingredient is not a skin sensitizer. Not acutely toxic (based on animal data).
Known Clinical Effects: Diarrhea is the most common side effect seen during clinical use.

Acute Toxicity: (Species, Route, End Point, Dose)
#### 11. TOXICOLOGICAL INFORMATION

<table>
<thead>
<tr>
<th>Material Name</th>
<th>Study Type</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>End Point</th>
<th>Target Organ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nelfinavir Mesylate</td>
<td>Oral</td>
<td>Rat</td>
<td>LD50</td>
<td>&gt; 1000 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>Mouse</td>
<td>LD50</td>
<td>&gt; 1000 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dermal</td>
<td>Rat</td>
<td>LD50</td>
<td>&gt; 2000 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nelfinavir Mesylate</td>
<td>Oral</td>
<td>Rat</td>
<td>LD50</td>
<td>&gt; 2000 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>Mouse</td>
<td>LD50</td>
<td>&gt; 2500 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>Rat</td>
<td>LD50</td>
<td>&gt; 10,000 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>Mouse</td>
<td>LD50</td>
<td>&gt; 1100 mg/kg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

**Irritation / Sensitization: (Study Type, Species, Severity)**

- **Nelfinavir Mesylate**
  - Skin Sensitization - Beuhler Guinea Pig Negative

**Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

- **Nelfinavir Mesylate**
  - 26 Week(s) Rat Oral 1000 mg/kg/day LOAEL Liver
  - 26 Week(s) Monkey Oral 250 mg/kg/day LOAEL Gastrointestinal system

**Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

- **Nelfinavir Mesylate**
  - Reproductive & Fertility Rat Oral 1000 mg/kg/day NOAEL No effects at maximum dose
  - Embryo / Fetal Development Rat Oral 1000 mg/kg/day NOAEL Not Teratogenic
  - Embryo / Fetal Development Rabbit Oral 1000 mg/kg/day NOAEL Not Teratogenic

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

- **FD&C Blue No. 2**
  - Bacterial Mutagenicity (Ames) *Salmonella* Negative

- **In Vitro Bacterial Mutagenicity (Ames)**
  - *Salmonella*, *E. coli* Negative

- **In Vitro Chromosome Aberration**
  - Human Lymphocytes Negative

- **In Vivo Micronucleus**
  - Mouse Bone Marrow Negative
11. TOXICOLOGICAL INFORMATION

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Nelfinavir Mesylate
2 Year(s)  Rat  Oral  300 mg/kg/day  LOAEL  Thyroid, neoplasms
2 Year(s)  Mouse  Oral  1000 mg/kg/day  NOAEL  Not carcinogenic

Carcinogen Status:  None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Crosopovidone
IARC:  Group 3 (Not Classifiable)

Colloidal silicon dioxide
IARC:  Group 3 (Not Classifiable)
NTP:  Reasonably Anticipated To Be A Human Carcinogen

12. ECOLOGICAL INFORMATION

Environmental Overview:  The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

Toxicity:  No data available

Persistence and Degradability:  No data available

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)
Nelfinavir Mesylate
Predicted  N/A  Log D  4.07

Mobility in Soil:  No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:  Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Colloidal silicon dioxide
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 231-545-4

Crospovidone
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: Not Listed

FD&C Blue No. 2
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 212-728-8

Magnesium stearate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 209-150-3

Nelfinavir Mesylate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
- EU EINECS/ELINCS List: Not Listed

Calcium stearate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
15. REGULATORY INFORMATION

EU EINECS/ELINCS List 216-472-8

Triacetin
- CERCLA/SARA 313 Emission reporting Not Listed
- California Proposition 65 Not Listed
- Inventory - United States TSCA - Sect. 8(b) Present
- Australia (AICS): Present
- EU EINECS/ELINCS List 203-051-9

Hydroxypropyl methylcellulose
- CERCLA/SARA 313 Emission reporting Not Listed
- California Proposition 65 Not Listed
- Inventory - United States TSCA - Sect. 8(b) Present
- Australia (AICS): Present
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
- EU EINECS/ELINCS List Not Listed

16. OTHER INFORMATION

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection.

Revision date: 03-Nov-2016

Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet